WHO Raises Warning Over Critical Shortage of Obesity Medications

Fewer than 10% of patients who could benefit from obesity jabs such as Wegovy have access to them, states the WHO as it releases its inaugural guidance on the drugs.

Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable access to GLP-1 medication.

Per estimates, in excess of 2,000,000,000 will be obese by 2030 without intervention.

"The new guidelines affirms that obesity is a long-term condition that can be treated with comprehensive and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are major barriers to broad availability to the treatments that can help people shift substantial body mass, says the body.

GLP-1 Therapy Supply Crisis

Despite the present best projected outlook, the manufacturing of these medications could only cover about 100 million people – under 10% of eligible patients, according to the health organization.

The guideline urges nations and manufacturers to widen availability, through strategies such as voluntary licensing.

The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.

How Weight-Loss Jabs Function

These medications imitate a natural hormone to slow digestion, suppress the appetite and enhance the sense of being full so users eat less.

Patients typically begin shedding pounds within a few weeks of beginning the weekly injections.

Research suggests people may regain a significant portion a year later of halting the drug, because their normal appetite resume.

Being carrying excess weight increases your chance for contracting health problems, such as diabetes, heart disease, stroke, and specific malignancies.

Excess weight affects people in all nations and was responsible for millions of fatalities worldwide in 2024, as per the WHO.